Socio-demographic and therapeutic profile of people living with thalassemia in Brazil between 2012 and 2022: A cross-sectional study
Hematology, Transfusion and Cell Therapy · Published 2026-05-02 · DOI 10.1016/j.htct.2026.106461
Free full text
Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.htct.2026.106461
Abstract
Objective: To outline the sociodemographic and therapeutic profile of individuals with thalassemia in Brazil between 2012 and 2022, by analyzing data from the Ministry of Health on outpatient care, hospitalization, and mortality records. Methods: This descriptive, cross-sectional study utilized secondary data from the Outpatient, Hospital, and Mortality Information Systems of the Ministry of Health on patients diagnosed with thalassemia (ICD-10 D56). Analyzed variables included demographics (sex, age, race/ethnicity), geographic location (residence and treatment site), and clinical outcomes (procedures, hospitalizations, and deaths). Results: In 2022, an estimated 662 patients received outpatient treatment in the Brazilian Unified Health System (SUS), with a predominance of young adults, women, and individuals self-identified as White, who were mostly concentrated in the southeastern and southern regions of the country. Red blood cell transfusion was the most frequently performed outpatient procedure during the period. There were 1278 hospitalizations, mainly of children aged 0–9 years. A total of 153 deaths were recorded, primarily among people aged 50 years or older. The findings characterize the patient profile, identify significant travel challenges to receive treatment, and suggest potential underreporting within reference institutions. Conclusion: It is essential to improve data recording in public databases to support specific health policies and ensure comprehensive, equitable, and continuous treatment for people living with thalassemia in Brazil.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Publication details
- Year
- 2026
Related articles
- LIPOSOMAL NANOFORMULATION OF A COPPER-BASED COMPLEX ASSOCIATED WITH PARPI MODULATES ANGIOGENIC PROCESSES IN ENDOTHELIAL CELLS · Hematology, Transfusion and Cell Therapy · 2026 · Same journal
- THERANOSTIC APPLICATION OF PSMA IN ADENOID CYSTIC CARCINOMA: ¹⁸F-PSMA PET/CT IMAGING AND ¹⁷⁷LU-PSMA THERAPY — A CASE REPORT · Hematology, Transfusion and Cell Therapy · 2026 · Same journal
- Hemovigilance in a Brazilian Amazon blood center: A temporal analysis of 5-year consumption patterns · Hematology, Transfusion and Cell Therapy · 2026 · Same journal
- EGFR-TARGETING GE11-DERIVED PEPTIDE DIFFERENTIALLY MODULATES TRIPLE-NEGATIVE BREAST CANCER AND GLIOBLASTOMA CELL PROLIFERATION IN VITRO · Hematology, Transfusion and Cell Therapy · 2026 · Same journal
- Therapeutic plasma exchange in acute liver failure: Unravelling its efficacy and impact · Hematology, Transfusion and Cell Therapy · 2026 · Same journal
- RACIAL DISPARITIES IN BRAZILIAN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: EXPLORATORY ANALYSIS OF EPIDEMIOLOGICAL PROFILE AND IMMUNE SENESCENCE/EXHAUSTION PROTEINS · Hematology, Transfusion and Cell Therapy · 2026 · Same journal
- CT-DERIVED BODY COMPOSITION AND MACHINE LEARNING FOR PROGNOSTIC IMPROVEMENT IN COLORECTAL CANCER · Hematology, Transfusion and Cell Therapy · 2026 · Same journal
- Mineral disorders after hematopoietic stem cell transplantation in patients receiving parenteral nutrition · Hematology, Transfusion and Cell Therapy · 2026 · Same journal
- False-positive test results: prevalence, time trends, and factors associated with false-positive serological markers in blood donation screening · Hematology, Transfusion and Cell Therapy · 2026 · Same journal
- Genetic diversity of the RHD gene in blood donors from the Brazilian Central-West · Hematology, Transfusion and Cell Therapy · 2026 · Same journal